Sufentanil Sublingual Tablet System: from rationale of use to clinical practice
- Autori: Vergari, A; Cortegiani, A; Rispoli, M; Coluzzi, F; Deni, F; Leykin, Y; Luca Lorini, F; Martorano, P P; Paolicchi, A; Polati, E; Scardino, M; Corcione, A; Giarratano, A; Rossi, M
- Anno di pubblicazione: 2020
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/469403
The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protocols for the use of this device.